BioSight
Companies
IRONWOOD PHARMACEUTICALS INC logo

IRWD

NASDAQBOSTON, MA
IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals develops and commercializes therapies for gastrointestinal and rare diseases, with LINZESS (linaclotide) as its marketed product for constipation-related conditions like IBS-C and chronic idiopathic constipation, sold globally through partnerships with AbbVie, AstraZeneca, and Astellas. Following its 2023 acquisition of VectivBio, Ironwood is advancing apraglutide, a GLP-2 peptide analog in late-stage clinical development for short bowel syndrome, with positive Phase III results announced in early 2024.

Price history not yet available for IRWD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar